CHORI Staff Directory
CHORI Intranet

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

The Big Picture
Active Clinical Studies at Children's Hospital & Research Center at Oakland

By Principal Investigator:
Principal Investigator Title IRB#:
Garcia, Jacob MD A Phase I Trial of NECTAR (Nelarabine, Etoposide and Cyclophosphamide in T-ALL Relapse): A Joint Study of TACL and POETIC 2010-007
Gilgoff, Rachel  MD Hypopharyngeal and Retropharyngeal Perforation: A Concern for Child Physical Abuse? 2012-037
Golden, Carla MD A Protocol for Collecting Follow-Up Data on Children's Cancer Group (and Other) Studies CHO-LFTU-1 1996-014
Golden, Carla MD Escalating Dose Intravenous Methotrexate
without Leucovorin Rescue vs Oral
Methotrexate and Single vs Double Delayed
Intensification Therapy for Children with
Standard Risk Acute Lymphoblastic Leukemia (COG 1991)
2000-049
Golden, Carla MD Neuroblastoma Biology Studies (ANBL00B1) 2001-058
Golden, Carla MD High Risk B-Precursor Acute Lymphoblastic Leukemia, A Phase III Group-Wide Study (COG AALL0232) 2004-025
Golden, Carla MD Classification of Acute Lymphoblastic Leukemia for Collection of Additional Bone Marrow (AALL03B1) 2004-027
Golden, Carla MD A Phase III Study of Reduced Therapy in the Treatment of Children with Low and Intermediate Risk Germ Cell Tumors 2004-049
Golden, Carla MD A Study Evaluating Limited Target Volume Boost Irradiation and Reduced Dose Craniospinal Radiotherapy (18.00 Gy) and Chemotherapy in Children with Newly Diagnosed Standard Risk Medulloblastoma: A Phase III Double Randomized Trial ACNS00331 2004-085
Golden, Carla MD Vincristine, Dactinomycin, and Lower Doses of Cyclophosphamide With or Without Radiation Therapy for Patients with Newly Diagnosed Low-Risk Embryonal/Botryoid Rhabdomyosarcoma (ARST0331) 2005-100
Golden, Carla MD Standard Risk B-Precursor Acute Lymphoblastic Leukemia (COG AALL0331) 2005-050
Golden, Carla MD Key Adverse Events Following Childhood Cancer (ALTE03N1) 2005-059
Golden, Carla MD Phase III Randomized Study of Chimeric Antibody 14.18 (Ch14.18) in High Risk Neuroblastoma Following Myeloablative Therapy and Autologous Stem Cell Rescue (ANBL0032) 2005-007
Golden, Carla MD Treatment of Late Isolated Extramedullary Relapse from Acute Lymphoblastic Leukemia (ALL) (initial CR1> 18 Months) (AALL02P2) 2005-008
Golden, Carla MD Soft Tissue Sarcoma Diagnosis, Biology and Banking Protocol, (COG-D9902) 2006-012
Golden, Carla MD A Randomized Trial of the European and American Osteosarcoma Study Group to Optimize Treatment Strategies for Resectable Osteosarcoma Based on Histologic Response to Pre-Operative Chemotherapy (EURAMOS 1) (AOST0331) 2006-017
Golden, Carla MD Protocol for Collecting and Banking Pediatric Research Specimens Including Rare Pediatric Tumors (COG ABTR01B1) 2006-034
Golden, Carla MD Renal Tumors Classification, Biology and Banking Study (COG-AREN03B2) 2006-050
Golden, Calra MD A Phase III Randomized Trial of Gemtuzumab Ozogamicin (Mylotarg®) Combined with Conventional Chemotherapy for De Novo Acute Myeloid Leukemia (AML) in Children, Adolescents, and Young Adults (AAML0531) 2006-083
Golden, Calra MD Intensified Methotrexate, Nelarabine (Compound 506U78; IND # 52611) and Augmented BFM Therapy for Children and Young Adults with Newly Diagnosed T-cell Acute Lymphoblastic Leukemia (AALL0434) 2007-019
Golden, Calra MD Randomized Study of Vincristine, Dactinomycin and Cyclophosphamide (VAC) versus VAC Alternating with Vincristine and Irinotecan (VI) for Patients with Intermediate-Risk Rhabdomyosarcoma (RMS) (ARST0531) 2007-041
Golden, Calra MD Treatment of Newly Diagnosed Higher Risk Favorable Histology Wilms Tumors (AREN0533) 2007-042
Golden, Calra MD Intensive Treatment for Intermediate-Risk Relapse of Childhood B-Precursor Acute Lymphoblastic Leukemia (ALL): A Randomized Trial of Vincristine Strategies AALL0433) 2007-055
Golden, Calra MD ANBL0531: Response and Biology-Based Therapy for Intermediate-Risk Neuroblastoma 2007-080
Golden, Calra MD A Phase III Study of Risk Directed Therapy for Infants with Acute Lymphoblastic Leukemia (ALL): Randomization of Highest Risk Infants to Intensive Chemotherapy +/- FLT3 Inhibition (CEP-701, Lestaurtinib; IND#76431; NSC#617807) (AALL0631) 2008-027
Golden, Calra MD Collecting and Banking Ewing Sarcoma Specimens (AEWS07B1) 2008-036
Golden, Calra MD Treatment for Very Low and Standard Risk Favorable Histology Wilms Tumor (AREN0532) 2008-047
Golden, Calra MD AAML0431, The Treatment of Down Syndrome Children with Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS) Under the Age of 4 Years 2008-050
Golden, Calra MD Phase III Trial of Single vs. Tandem Myeloablative Consolidation Therapy for High-Risk Neuroblastoma (ANBL0532) 2009-028
Golden, Calra MD Risk Adapted Treatment of Newly Diagnosed Childhood Acute Promyelocytic Leukemia (APL) using Arsenic Trioxide (Trisenox® IND# 103, 331) during Consolidation (AAML0631) 2009-031
Golden, Calra MD Cardiac Structure and Function After Enzyme Replacement Therapy for Mucopolysaccharidosis Type VI: Analysis of Results From ASB-00-01, ASB-01-04, ASB-03-05, ASB-03-06 2009-089
Golden, Calra MD A Phase II Pilot Study of Bortezomib (PS-341, Velcade, IND# 58,443) Combined with Reinduction Chemotherapy in Children and Young Adults with Recurrent, Refractory or Secondary Acute Myeloid Leukemia (AAML07P1) 2010-001
Golden, Calra MD Treatment of Children with Newly-Diagnosed Low Stage Lymphocyte Predominant Hodgkin Disease (LPHD) (AHOD03P1) 2010-002
Golden, Calra MD A Phase II Pilot Trial of Bortezomib (PS-341, Velcade?, IND# 58,443) in Combination with Intensive Re-Induction Therapy for Children with Relapsed Acute Lymphoblastic Leukemia (ALL) and Lymphoblastic Lymphoma (LL) (AALL07P1) 2010-003
Golden, Calra MD Treatment of High Risk Renal Tumors: A Groupwide Phase II Study (AREN0321) 2010-008
Golden, Calra MD Classification of Newly Diagnosed Acute Lymphoblastic Leukemia (AALL08B1) 2010-073
Golden, Calra MD Treatment for Patients with Bilateral, Multicentric, or Bilaterally-Predisposed Unilateral Wilms Tumor (AREN0534) 2010-074
Golden, Calra MD A Pilot Study to Evaluate Novel Agents (Temozolomide and Cixutumumab) in Combination with Intensive Multi-Agent Interval Compressed Therapy for Patients with High-Risk Rhabdomyosarcoma (ARST08P1) 2010-094
Golden, Calra MD A Phase III Randomized Trial of Adding Vincristine-Topotecan-Cyclophosphamide to Standard Chemotherapy in Initial Treatment of Non-metastatic Ewing Sarcoma (AEWS1031) 2011-007
Golden, Calra MD A Randomized Phase II Trial of Bevacizumab (IND# 7921, Avastin) and Temsirolimus (IND# 61010, Torisel) in Combination with Intravenous Vinorelbine and Cyclophosphamide in Patients with Recurrent/Refractory Rhabdomyosarcoma: A Groupwide Phase II Study (ARST0921) 2011-008
Golden, Calra MD A Phase II Study of MLN8237 (IND# 102984), a Selective Aurora A Kinase Inhibitor in Children with Recurrent/Refractory Solid Tumors and Leukemias (ADVL0921) 2011-037
Golden, Calra MD AALL0932 Treatment of Patients with Newly Diagnosed Standard Risk B-Precursor Acute Lymphoblastic Leukemia (ALL): A Groupwide Phase III Study 2011-092
Golden, Calra MD AAML1031 A Phase III Randomized Trial for Patients with de novo AML using Bortezomib (IND#58443, NSC# 681239) and Sorafenib (BAY 43-9006, IND69896, NSC# 724772) for Patients with High Allelic Ratio FLT3/ITD 2011-093
Golden, Calra MD Biology Study of Transient Myeloproliferative Disorder (TMD) in Children with Down Syndrome (DS) (AAML08B1) 2011-097
Golden, Calra MD A Non-Randomized Phase III Study of Response Adapted Therapy for the Treatment of Children with Newly Diagnosed High Risk Hodgkin Lymphoma: A Groupwide Phase III Study (AHOD0831) 2011-098
Golden, Calra MD AALL1131, A Phase III Randomized Trial for Newly Diagnosed High Risk B-precursor Acute Lymphoblastic Leukemia (ALL) Testing Clofarabine (IND# 73789, NSC# 606869) in the Very High Risk
Stratum: A Groupwide Phase III Study
2012-020
Golden, Carla  MD ADVL1221, A Phase II Study of Cixutumumab (IMC-A12; IND# 100947) in Combination with Temsirolimus (IND# 61010) in Pediatric Patients with Recurrent or Refractory Solid Tumors 2012-069
Golden, Carla  MD Intergroup Trial for Children or Adolescents with B-Cell NHL or B-AL: Evaluation of Rituximab Efficacy and Safety in High Risk Patients (ANHL1131) 2012-087
Gomez, Ann PhD, RCP, Survey of Staff with Experience Using Heat Humidified Nasal Cannula Therapy 2005-056
Gomez, Esteban MD Effects of iron overload on the mitochondrial genome in patients with thalassemia 2013-004
Granoff, Dan MD Human Serum for Use in Bactericidal Assays 2002-010
Granoff, Dan MD Expedited Review of a Proposed Investigation on Stored Sera from Uganda 2002-020
Granoff, Dan MD Expedited Review of Proposed Investigations of Stored Sera: Sudan Study 2002-023
Granoff, Dan MD Expedited Review of Proposed Investigations of Stored Sera: GSK Meningococcal Conjugate and Polysaccharide Immunogenicity Study: Czech Republic/Belgium 2002-024
Granoff, Dan MD Immunity to Meningococcal Polysaccharide Vaccine (Menomune) 2002-034
Granoff, Dan MD Proposed Investigations of Stored Sera: Canadian Meningococcal Immunogenicity Study 2002-006
Granoff, Dan MD A Phase 2, Randomized, Single-Center, Controlled Study to Evaluate the Safety, Immunogenicity and Priming Ability of the Chiron Meningococcal C Conjugate Vaccine in Adults at Risk for Meningococcal Serogroup C Exposure or Disease 2003-016
Granoff, Dan MD A Phase I, Open-Label, Uncontrolled, Single-Center, Extension Study of the Safety, Tolerability, and Immunogenicity of the Chiron Recombinant Meningococcal B G 287 Vaccine in Healthy Adults who Previously Completed Study MB1001 2004-018
Granoff, Dan MD Expedited Review of Proposed Investigations Using Whole Blood for Bacterial Growth Assays 2004-039
Granoff, Dan MD Human Serum for Use in Bactericidal Assays: Screening to Find Suitable Donors (Aventis Study) 2005-002
Granoff, Dan MD Human Serum for Use as Complement: Collection from Previously Identified Donors (Sanofi Study) 2005-068
Hagar, Ward MD ER and Hospitalization Utilization Patterns Before and After Joining a Comprehensice Sickle Cell Center 2005-073
Hardy, Karen MD Cystic Fibrosis Patient Registry 2003-001
Hardy, Karen MD Barriers to Adherence in Giving Inhaled Corticosteriods to Children with Chronic Persistent Asthma 2004-071
Hardy, Karen MD Retrospective Review of Alveolar Hemorrhage  of CHRCO experience in past 30 years 2007-023
Hardy, Karen MD Sweat Testing in Cystic Fibrosis Newborns Detected by Screening 2009-052
Hardy, Karen MD Modifier Genes in Latino/Hispanic Patients with Cystic Fibrosis 2010-029
Hardy, Karen  MD A 6 Month Safety and Benefit Study of Inhaled Fluticasone Propionate/Salmeterol Combination Versus Inhaled Fluticasone Propionate in the Treatment of 6,200 Pediatric Subjects 4-11 Years Old with Persistent Asthma 2012-002
Hardy, Karen  MD A Long-Term Prospective Observational Safety Study of the Incidence of and Risk Factors for Fibrosing Colonopathy in US Patients with Cystic Fibrosis Treated with Pancreatic Enzyme Replacement Therapy: A Harmonized Protocol Across Sponsors 2012-044
Hardy, Karen  MD Clofazimine Treatment for Mycobacterium Avium Complex in a Patient with Cystic Fibrosis 2012-063
Harmatz, Paul MD Natural History of Iron Burden and Risk of Organ Injury as Assessed and Predicted by Non-Invasive Measurement Techniques 2002-075
Harmatz, Paul MD Validation of Biosusceptometry as a Non-Invasive Technique for Assessment of Liver Iron 2003-026
Harmatz, Paul MD Calibration of SQUID Biosusceptometry Instruments as a Non-Invasive Technique for Assessment of Liver Iron 2003-076
Harmatz, Paul MD Early Detection of Iron Cardiomyopathy in Thalassemia (EDICT 2005-011
Harmatz, Paul MD MPS VI Clinical Surveillance Program 2005-062
Harmatz, Paul MD Magnetic Resonance Imaging (MRI) Protocol Development and Quality Assurance 2005-064
Harmatz, Paul MD Comparison between a Low Cost Cryobiosusceptometer and Ferritometer as a Non-Invasive Technique for Assessment of Liver Iron 2006-010
Harmatz, Paul MD Hunter Outcome Survey (HOS): A Global, Multi-Center, Long-Term, Observational Survey of Patients with Hunter Syndrome (Mucopolysaccharidosis II) 2006-067
Harmatz, Paul MD A Randomized, Double-Blind Evaluation of the Antiviral Efficacy,
Safety, and Tolerabiliity of Tenofovir Disoproxil Fumarate Versus
Placebo in Adolescents with Chronic Hepatitis B infection
GS-US-174-0115
2008-057
Harmatz, Paul MD A Multicenter, Multinational, Cross-sectional Clinical Assessment Study of Subjects with Mucopolysaccharidosis IVA (Morquio Syndrome) 2008-054
Harmatz, Paul MD IRISS Study: Intervention for (those) Recently Informed of Seropositive Status 2008-073
Harmatz, Paul MD A Multicenter, Prospective, Long-term, Observational Registry of Pediatric Patients with Inflammatory Bowel Disease 2008-078
Harmatz, Paul MD A Study of Intrathecal Enzyme Replacement for Cognitive Decline in Mucopolysaccharidosis I 2010-031
Harmatz, Paul MD Longitudinal Studies of Brain Structure and Function in MPS Disorders 2010-046
Harmatz, Paul MD REPLAGAL (agalsidase alfa) for Use in Fabry Disease; expanded access 2010-053
Harmatz, Paul MD Development and Validation of Newborn Screening Assays to Measure Biomarkers and Enzyme Levels in Biological Samples from Patients with a Lysosomal Storage Disorder and Their Relatives 2011-015
Harmatz, Paul MD MOR-004: A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multinational Clinical Study to Evaluate the Efficacy and Safety of BMN 110 in Patients with Mucopolysaccharidosis IVA (Morquio A Syndrome) 2011-021
Harmatz, Paul MD An Open-Label, Multicenter, Multinational Study of the Safety, Efficacy and Pharmacokinetics of ENB-0040 (Enobia's human recombinant tissue non-specific alkaline phosphatase fusion protein) in Infants and Children < 5 Years of Age with Hypophosphatasia (HPP) 2011-025
Harmatz, Paul MD MOR-005: A Multicenter, Multinational, Extension Study to Evaluate the Long-Term Efficacy and Safety of BMN 110 in Patients with Mucopolysaccharidosis IVA (Morquio A Syndrome) 2011-074
Harmatz, Paul MD MOR-007: A Phase 2, Open-label, Multinational Clinical Study to Evaluate the Safety and Efficacy of BMN 110 in Pediatric Patients Less Than 5 Years of Age with Mucopolysaccharidosis IVA (Morquio A 2011-084
Harmatz, Paul MD MOR-008: A Randomized, Double-Blind, Pilot Study of the Safety and Physiological Effects of Two Doses of BMN 110 in Patients with Mucopolysaccharidosis IVA (Morquio A Syndrome) 2012-007
Harmatz, Paul MD MOR-006: A Phase 2, Open-label, Multinational Study to Evaluate the Efficacy and Safety of BMN 110 in Patients with Mucopolysaccharidosis IVA (Morquio A Syndrome) Who Have Limited Ambulation 2012-008
Harmatz, Paul MD A Phase 4, Open-Label, Prospective Study in Patients with Pompe Disease to Evaluate the Efficacy and Safety of Alglucosidase Alfa Produced at the 4000 L Scale 2012-010
Harmatz, Paul MD A Multicenter, Multinational Clinical Assessment Study for Pediatric Patients with Achondroplasia 2012-018
Harmatz, Paul  MD A Phase 2, Open-label, Multicentre, Extension Safety and Tolerability Study for Transfusionally Iron Overloaded Children, Adolescents and Adults Using FBS0701 (SSP-004184) 2012-056
Harmatz, Paul  MD A Phase 3/4, Multinational, Open-Label Non-Inferiority Study of Alglucosidase Alfa Manufactured at the 160 L and 4000 L Scales in Treatment-Naïve Patients with Infantile-Onset Pompe Disease 2012-060
Harmatz, Paul  MD A Prospective, Longitudinal, Observational Study to Evaluate Neurodevelopmental Status in Pediatric Patients with Hunter Syndrome (MPS II) 2012-078
Harmatz, Paul  MD A Randomized, Double-Blind Evaluation of the Antiviral Efficacy, Safety, and Tolerability of Tenofovir Disoproxil Fumarate Versus Placebo in Pediatric Patients with Chronic Hepatitis B Infection 2012-079
Harmatz, Paul  MD An Observational Prospective Natural History Study of Patients with Mucopolysaccharidosis Type IIIB (MPS IIIB, Sanfilippo Syndrome Type B) 2012-086
Harmatz, Paul  MD A Multicenter, Open-label BMN 110 US Expanded Access Program (BMN 110 US EAP) to Provide BMN 110 to Patients Diagnosed with MPS IVA 2013-017
Hastings, Caroline, MD Intrathecal Delivery of HPBCD for Niemann Pick Type C Patients 2010-070
Hastings, Caroline, MD A Study of Intrathecal and Intravenous Hydroxy-Propyl-Beta-Cyclodextrin (HPBCD) for the Treatment of Cognitive Decline in Niemann Pick Type C Disease 2011-085
Hastings, Caroline, MD Pediatric Hematology/Oncology Fellow Career Exploration Project 2011-094
Hastings, Caroline  MD Are surveillance CT scans of the pelvis of benefit for children treated for sWilms Tumor or hepatoblastoma?" 2012-050
Hoffinger, Scott, MD Long Term Follow-Up of Open Reduction Femoral Osteotomy in Children with Cerebral Palsy 2010-084
Hoffinger, Scott, MD Prevalence of pain during hip impingement test in normal non-symptomatic children 2011-033
Hoppe, Carolyn MD Phase I/II Study of Simvastatin (Zocur) Therapy in Sickle Cell Disease 2006-037
Hoppe, Carolyn MD Analysis of Rh Blood Group Genes to Improve Transfusion Therapy in Sickle Cell Disease 2007-061
Hoppe, Carolyn MD Specimen Banking for Future Sickle Cell Disease Research 2010-024
Hoppe, Carolyn MD Effect of Simvastatin Treatment on Vaso-occlusive Pain in Sickle Cell Disease 2011-089
Houtchens, Kathleen PhD Novel MALDI-TOF Assay for Rapid KIR Complex Sequencing 2004-090
Hsieh, Charlotte MD Use of Throw-Away Samples for Validation of In-House PCR Assays 2005-023
Hui, Thomas T. MD Identification of Genetic, Immunologic and Microbial Markers of Hirschsprung Associated Enterocolitis in Children with Hirschsprung Disease 2011-057
Illek, Beate PhD Translational Research Center for CAM Therapy and Asthma 2005-031
Revised: Monday, May 13, 2013 12:52 PM

© 2005 Children's Hospital Oakland Research Institute
5700 Martin Luther King Jr Way • Oakland, California 94609
Phone 510-450-7600 • Fax 510-450-7910
Site MapDisclaimer

208